

June 1, 2026 – Policy update to Attachment B

340B In-House Pharmacy Policy

Dear 340B Covered Entity,

AstraZeneca is introducing an In-house Pharmacy Policy effective May 1, 2026. This In-house Pharmacy Policy expands on our existing 340B Contract Pharmacy Policy, resulting in a universal claims requirement for all 340B utilization of specified products in our portfolio. Under this policy, all Covered Entities must submit 340B claims data, including in-house pharmacy dispenses, via the 340B ESP platform.

For products listed in *Attachment B*, all 340B pharmacy and medical claims must be submitted within 45 days of the dispense date to the Covered Entity's patient. Failure to provide complete, timely, and accurate claims data may result in suspension of access to 340B pricing for the applicable products, until the required data is received and validated.

As the 340B landscape continues to evolve, AstraZeneca continually strives to strengthen the integrity and transparency of the 340B program and ensure it is used appropriately to support the vulnerable patients it was designed to serve. The universal claims requirement will reinforce appropriate use, minimize diversion, and reduce duplicate discounts. The requested data encompass the routine claims information already collected by Covered Entities and third-party administrators to facilitate replenishment of dispensed 340B products and are consistent with the Contract Pharmacy claims data AstraZeneca has collected since October 2024.

Covered Entities who are not currently submitting data can do so by registering at www.340BESP.com. The 340B ESP platform is the only platform for a Covered Entity to submit claims data under AstraZeneca's policy. Please see www.340BESP.com for additional details on submitting claims data, including the limited set of required data fields.

If you have any questions regarding this policy, please contact AstraZeneca at 340B@astrazeneca.com.

Attachment A: Frequently Asked Questions

Q. How does AstraZeneca define in-house pharmacy?

A. An in-house pharmacy is one owned by the 340B covered entity and identified by HRSA OPAIS under either “Street Address” or “Shipping Addresses.”

Q. Which products are subject to AstraZeneca’s In-House Policy?

A: AstraZeneca’s in-house pharmacy policy applies to the products in Attachment B. AstraZeneca will inform covered entities of any changes to the product list. Both the AstraZeneca In-house Pharmacy Policy and up to date list of included products can be found on www.340BESP.com.

Q. My Covered Entity currently submits claims to the 340B ESP platform for my Contract Pharmacies. Does my Covered Entity now have to submit claims for dispenses at my in-house pharmacy(s)?

A: If you currently submit AstraZeneca claims to 340B ESP, it indicates your in-house pharmacy does not dispense AstraZeneca products and you have designated a single contract pharmacy. Please continue submitting claims per AstraZeneca’s Contract Pharmacy Policy. If you later begin dispensing AstraZeneca products in-house, 340B pricing to the contract pharmacy will be suspended, and you will instead submit 340B claims for dispenses from your in-house pharmacy.

Q. How will AstraZeneca use the submitted 340B pharmacy and medical claims data?

A: AstraZeneca is committed to program transparency and integrity and has a statutory obligation to prevent duplicate discounts. Claims data allows AstraZeneca to confirm that dispenses are 340B eligible, enables more accurate deduplication between 340B discounts and Medicaid or Inflation Reduction Act Medicare Drug Price Negotiation rebates, and supports detection of potential diversion.

Q: What are the requirements for submitting 340B claims data?

A: The new claims data submission requirement applies to all Covered Entities with an in-house pharmacy location across all states. All specified claims data must be submitted within 45 days of the date of dispense to your Covered Entity’s patient. If purchases at an in-house pharmacy location exceed conforming claims submitted according to this policy, this may result in a suspension of 340B priced medicines. Please see www.340BESP.com for additional details on submitting claims data, including the limited set of required data fields.

**Attachment B:
In Scope Product List**

AIRSUPRA®

BAXFENDY™

BEVESPI AEROSPHERE®

BREZTRI AEROSPHERE™

BRILINTA®

BYDUREON®

BYETTA®

CRESTOR®

DALIRESP®

FARXIGA®

FASENRA®

KOMBIGLYZE® XR

LOKELMA™

NEXIUM®

ONGLYZA®

PULMICORT®

QTERN®

SYMBICORT®

SYMLIN®

XIGDUO® XR